Nektar Therapeutics Reports Narrowed Q1 Loss, Strengthened Cash Position to Over $1 Billion, and Advances Lead Candidate to Phase 3
NKTR has more than doubled off its 52-week low of $7.99.
Summary
Nektar Therapeutics reported a narrowed Q1 net loss, a substantial increase in cash and investments to over $1 billion, and key advancements for its lead drug candidate, rezpegaldesleukin, into late-stage clinical development.
Key Events · Earnings and Guidance · NKTR
-
Q1 Financial Results Show Improvement
The company reported a Q1 2026 net loss of $44.9 million ($1.82 per share), a significant narrowing from $50.9 million ($3.62 per share) in Q1 2025. Total operating costs and expenses decreased to $49.9 million from $55.0 million year-over-year.
-
Cash Position Exceeds $1 Billion
Cash and investments in marketable securities reached $731.6 million as of March 31, 2026. This figure excludes approximately $351 million in net proceeds from a secondary offering completed on April 23, 2026, bringing the total cash and investments to over $1 billion, significantly extending the company's financial runway.
-
Lead Candidate Advances to Phase 3
Nektar's lead biologic candidate, rezpegaldesleukin, is set to initiate its Phase 3 ZENITH-AD program in moderate-to-severe atopic dermatitis by July 2026. An End-of-Phase 2 meeting with the FDA for alopecia areata is also scheduled for Q2 2026.
Analysis · NKTR · Life Sciences
Nektar Therapeutics reported a significantly improved financial position in Q1 2026, with a narrowed net loss and reduced operating costs. The company's cash and investments surged to over $1 billion following successful public offerings in February and April, providing a substantial runway for its clinical development programs. This strengthened balance sheet is a critical de-risking event for a clinical-stage biotechnology company. Furthermore, the company announced the advancement of its lead biologic candidate, rezpegaldesleukin, into a Phase 3 program for atopic dermatitis by July 2026 and an End-of-Phase 2 meeting for alopecia areata in Q2 2026, signaling significant progress in its pipeline.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1062 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $82.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $7.99 to $109.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.